Purchase this article with an account.
Kyung Tae Kang, Yu Cheol Kim, Kwang-Soo Kim; The factors affect repetitive injections of intravitreal Bevacizumab in patients with branch retinal vein occlusion. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3887.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To identify the factors that affect repeatability of intravitreal Bevacizumab injection in patients with branch retinal vein occlusion.
A total of 26 patients with macular edema secondary to branch retinal vein occlusion(B.R.V.O.) within 1 month since diagnosis were examined. Initial best corrected visual acuity, central macular thickness, type of branch retinal vein occlusion according to the involved vein branch, lens status, distance between fovea and occlusion site, type of macular edema, presence of macula hemorrhage, presence of capillary nonperfusion were evaluated at the time of diagnosis. The patients had an intravitreal Bevacizumab injection at the time of diagnosis, and had reinjections when macular edema and visual acuity aggravated. Presence of focal laser treatment during followup period was also evaluated. According to each considering factors, the free of reinjection rate which was considered to be survival rate was evaluated during 1 year since the first injection.
The patients with initial visual acuity better than LogMAR 0.5 showed 52.6% survival rate within 1yr compare to 14.3% of the patients with visual acuity worse than LogMAR 0.5(p<0.01). The patients with occluded site closer than distance of 2.5 Disc Diameter from fovea had 57.1% of survival rate, and the patients with occluded vein farther than distance of 2.5 Disc Diameter from fovea had 25.0%(p=0.04). Macular B.R.V.O. and major B.R.V.O. patient had 25.0% and 71.5% of survival rate, respectively(P-0.01). Presence of capillary nonperfusion, central macular thickness, focal laser treatment, macular hemorrhage and lens status, macular edema type did not significantly affect the survival rate of the patients.
The patients with B.R.V.O. are suggested to have less chance of repetitive intravitreal Bevacizumab due to macular edema when initial visual acuity is better than LogMAR 0.5, occluded site is closer than 2.5DD from fovea, and macular branch is involved at the initial diagnosis.
This PDF is available to Subscribers Only